NANEXA Stock Overview
Operates as a nanotechnology drug delivery company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.51 |
| 52 Week High | SEK 3.15 |
| 52 Week Low | SEK 0.60 |
| Beta | 1.78 |
| 1 Month Change | 96.86% |
| 3 Month Change | 58.36% |
| 1 Year Change | 106.58% |
| 3 Year Change | -35.31% |
| 5 Year Change | -75.98% |
| Change since IPO | -74.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| NANEXA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -3.5% | 0.2% | -2.3% |
| 1Y | 106.6% | -8.1% | 4.6% |
Return vs Industry: NANEXA exceeded the Swedish Medical Equipment industry which returned -8.1% over the past year.
Return vs Market: NANEXA exceeded the Swedish Market which returned 4.6% over the past year.
Price Volatility
| NANEXA volatility | |
|---|---|
| NANEXA Average Weekly Movement | 15.1% |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: NANEXA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: NANEXA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 16 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
| NANEXA fundamental statistics | |
|---|---|
| Market cap | SEK 340.60m |
| Earnings (TTM) | -SEK 64.42m |
| Revenue (TTM) | SEK 50.76m |
6.7x
P/S Ratio-5.3x
P/E RatioIs NANEXA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NANEXA income statement (TTM) | |
|---|---|
| Revenue | SEK 50.76m |
| Cost of Revenue | SEK 18.08m |
| Gross Profit | SEK 32.69m |
| Other Expenses | SEK 97.11m |
| Earnings | -SEK 64.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 19, 2025
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 64.39% |
| Net Profit Margin | -126.91% |
| Debt/Equity Ratio | 1.5% |
How did NANEXA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 15:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanexa AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gonzalo Artiach Castanon | ABG Sundal Collier Sponsored |
| Fredrik Thor | Redeye |